drugset
drugset / Trial / NCT05865925

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

NCT05865925 ↗

Phase 1/2 Unknown 78 enrolled Luye Pharma Group Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open, dose escalation, single and multiple administration phase Ⅰ/Ⅱ clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and primary clinical efficacy of LY01616 in patients with advanced solid tumors

Timeline

Start
2021-04-22
Primary completion
2024-08-31
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LY010616 Unknown 30 mg/m2 Intravenous
Subject LY010616 Unknown 60 mg/m2 Intravenous
Subject LY010616 Unknown 90 mg/m2 Intravenous
Subject LY010616 Unknown 120 mg/m2 Intravenous
Subject LY010616 Unknown 150 mg/m2 Intravenous
Subject LY010616 Unknown 180 mg/m2 Intravenous

Indications

cancer